SCM launches sterility and endotoxin testing

- Last updated on GMT

Related tags: Management

SCM says addition of sterility and endotoxin analysis capacity is logical extension of its contract fill/finish offering.

The services are based at the UK contract manufacturing organisation’s (CMO) which managing director Dianne Sharp predicted would offer customers significant cost saving opportunities.

Not only will this reduce the potential risk of loss, breakage, documentation issues and delays associated with offsite testing but by allocating testing slots straight after sterile filling, our clients are likely to get their product even quicker​.”

The addition of the new services follows just a few weeks after SCM landed five new manufacturing contracts, which it said could be worth as much as £1.5m (€1.8m) a year.

These new deals were secured as a result of a global business expansion effort that will see the firm attend the American Association of Pharmaceutical Scientists (AAPS) trade show in New Orleans later this year.

Related news

Show more

Related products

Q2 Solutions: Corporate Brochure

Q2 Solutions: Corporate Brochure

Q2 Solutions | 17-Apr-2020 | Product Brochure

We are an innovative, progressive and responsive partner with the global experience, medical expertise and focus on quality that is integral to drug, medical...

Manufacturing Cyto and Non-Cyto Drugs in One Facility

Manufacturing Cyto and Non-Cyto Drugs in One Facility

Baxter BioPharma Solutions | 01-Mar-2020 | Technical / White Paper

Recent market reports suggest increasing product niches, which may lead to decreasing numbers of units per product, making dedicated facilities less practical....

Related suppliers

Follow us

Products

View more

Webinars